Top Page
Guardant Health
(NASDAQ:GH)
Guardant Health (GH) vs. SPDR S&P 500 ETF (SPY)
Guardant Health Business Overview & Revenue Model
Guardant Health Key Performance Indicators (KPIs)
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Main Street DataGuardant Health Earnings Call Summary
Guardant Health Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 902.57M | 739.02M | 563.95M | 449.54M | 373.65M | 286.73M |
| Gross Profit | 575.46M | 449.22M | 336.90M | 293.21M | 250.74M | 194.19M |
| EBITDA | -354.11M | -390.12M | -433.31M | -614.91M | -359.62M | -225.07M |
| Net Income | -398.79M | -436.37M | -479.45M | -654.59M | -405.67M | -253.78M |
Balance Sheet | ||||||
| Total Assets | 1.28B | 1.49B | 1.79B | 1.61B | 2.20B | 2.27B |
| Cash, Cash Equivalents and Short-Term Investments | 580.01M | 839.98M | 1.17B | 1.01B | 932.75M | 1.79B |
| Total Debt | 1.33B | 1.34B | 1.35B | 1.37B | 1.37B | 854.49M |
| Total Liabilities | 1.63B | 1.63B | 1.63B | 1.55B | 1.56B | 916.19M |
| Stockholders Equity | -354.47M | -139.65M | 158.68M | 60.18M | 645.00M | 1.30B |
Cash Flow | ||||||
| Free Cash Flow | -262.23M | -274.94M | -345.46M | -386.92M | -284.05M | -157.99M |
| Operating Cash Flow | -222.90M | -239.86M | -324.98M | -309.46M | -209.02M | -103.93M |
| Investing Cash Flow | 288.39M | -261.31M | 840.25M | 149.82M | -63.16M | -617.09M |
| Financing Cash Flow | -63.83M | -996.00K | 477.38M | -189.09M | -66.82M | 1.41B |
Guardant Health Technical Analysis
Guardant Health Risk Analysis
Guardant Health Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $26.96B | ― | -24.32% | ― | 44.38% | 22.87% | |
66 Neutral | $10.40B | 45.85 | 3.04% | 0.29% | 3.37% | -18.80% | |
66 Neutral | $9.55B | 25.78 | 10.81% | 2.91% | 5.15% | 412.41% | |
66 Neutral | $6.05B | -382.69 | -1.65% | ― | 11.33% | -232.27% | |
62 Neutral | $13.19B | ― | -34.54% | ― | 14.47% | -353.69% | |
54 Neutral | $12.37B | ― | ― | ― | 30.38% | 24.17% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Guardant Health Corporate Events
Guardant Health’s recent earnings call revealed a positive sentiment, highlighting strong revenue growth and operational achievements. The company’s success in its oncology and Shield testing businesses, alongside strategic partnerships and improved gross margins, underscores its robust market position. However, challenges such as increased operating expenses and uncertainties in future reimbursement and guideline inclusion were also acknowledged.
Guardant Health, a precision oncology company, focuses on enhancing cancer care through advanced blood and tissue tests, real-world data, and AI analytics. In its third-quarter 2025 earnings report, Guardant Health announced a 39% revenue increase, reaching $265.2 million, driven by strong performance in its Oncology, Screening, and Biopharma & Data segments. The company also raised its 2025 revenue guidance to $965 to $970 million, indicating a 31% year-over-year growth.
Study Overview: The SIBYL study, officially titled ‘obServation of Therapy Response With lIquid BiopsY evaLuation,’ aims to validate the clinical use of Guardant360, a liquid biopsy tool, in monitoring therapy responses in patients with advanced solid tumors. This study is significant as it seeks to establish the correlation between ctDNA dynamics and therapeutic outcomes, providing a non-invasive method to evaluate treatment efficacy.
Study Overview: The ORACLE study, officially titled ‘Observation of ResiduAl Cancer With Liquid Biopsy Evaluation,’ aims to demonstrate the efficacy of Guardant Health’s novel ctDNA assay in detecting cancer recurrence in patients treated for early-stage solid tumors. This study is significant as it seeks to establish the clinical validity of ctDNA tests in recurrence detection, potentially offering a cost-effective solution in healthcare environments.
Study Overview: The Shield Post-Approval Study Protocol by Guardant Health aims to assess the performance of the Shield blood test for colorectal cancer (CRC) screening in individuals aged 45 to 81 at average risk. This prospective, longitudinal study uses real-world evidence to validate the test’s efficacy, with colonoscopy as the reference standard.
Guardant Health, Inc. announced it will host an Investor Day on September 24, 2025, in New York City, featuring presentations from its co-CEOs and executive team to discuss the company’s operations, strategic priorities, and financial outlook. This event is expected to provide stakeholders with valuable insights into the company’s future direction and market positioning.
The most recent analyst rating on (GH) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Guardant Health stock, see the GH Stock Forecast page.
On September 12, 2025, Guardant Health expanded its Board of Directors to 11 members, appointing Alex M. Azar II, former U.S. Secretary of Health and Human Services, as a Class III director. Azar’s extensive experience in both government and the private sector is expected to provide valuable insights as Guardant Health continues to innovate in precision oncology and expand access to its cancer detection and management technologies.
The most recent analyst rating on (GH) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Guardant Health stock, see the GH Stock Forecast page.
Guardant Health’s recent earnings call conveyed a positive sentiment, highlighting robust performance across its major business segments. The company reported significant revenue growth and improved gross margins, despite minor concerns regarding ASP adjustments and regulatory uncertainties. The overall outlook remains optimistic, driven by strong execution and increased guidance.
Guardant Health, a precision oncology company, is at the forefront of transforming patient care through advanced blood and tissue tests, real-world data, and AI analytics to improve cancer treatment outcomes. In its latest earnings report, Guardant Health announced a robust 31% increase in total revenue for the second quarter of 2025, driven by strong performances across its Oncology, Screening, and Biopharma & Data segments. The company has also raised its 2025 revenue guidance to between $915 and $925 million, reflecting a growth of 24% to 25% over the previous year. Key financial highlights include a significant increase in Oncology revenue by 22% to $158.7 million, and Biopharma & Data revenue by 28% to $56.0 million. The company also reported a non-GAAP gross margin improvement to 66% from 60% in the previous year. Operating expenses rose due to the expansion of the commercial team and marketing activities, but the net loss narrowed slightly to $99.9 million from $102.6 million the previous year. Looking ahead, Guardant Health is optimistic about its growth trajectory, with expectations of continued revenue growth and strategic advancements in its product offerings, including the Shield multi-cancer detection test, which has received Breakthrough Device Designation from the FDA. The company remains committed to expanding its technical leadership in the genomic profiling market and enhancing its commercial infrastructure.